Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Audio-Described Menopause Education Program in Visually Impaired Women

17 augustus 2026 bijgewerkt door: İlknur Münevver Gönenç, Ankara University

The Effect of Education Provided Through Audio Description Method on Menopause Knowledge and Menopausal Symptoms in Visually Impaired Women: Randomized Controlled Trial

This randomized controlled trial was conducted to evaluate the effect of an audio-described menopause education program on menopause knowledge and menopausal symptoms in women with visual impairment. A total of 46 women who were members of the Ankara Branch of the Altı Nokta Blind Association were randomly assigned to either an intervention group (n=23) or a control group (n=23). The intervention group received an accessible menopause education program, while the control group did not receive the intervention during the study period. Outcomes included menopause knowledge and menopausal symptom severity, assessed using standardized measurement tools.

Studie Overzicht

Gedetailleerde beschrijving

This study was designed as a randomized controlled trial in accordance with CONSORT guidelines. It aimed to determine the effectiveness of an audio-described menopause symptom and awareness education program for women with visual impairment on menopause knowledge and menopausal symptoms.

The study sample consisted of 46 women who were members of the Ankara Branch of the Altı Nokta Blind Association. Participants were randomly allocated in a 1:1 ratio to either the intervention group (n=23) or the control group (n=23).

Data were collected using a demographic information form, the Menopause Knowledge Scale, and the Menopause Rating Scale. The intervention group received an audio-described educational program designed to improve accessibility for women with visual impairment, while the control group did not receive the intervention during the study period.

Statistical analyses included descriptive statistics, Fisher-Freeman-Halton Exact test, Pearson chi-square test, Cronbach's alpha reliability analysis, assessment of skewness and kurtosis for normality, Pearson correlation analysis, independent samples t-test, and analysis of covariance (ANCOVA). Statistical significance was set at p < 0.05.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

46

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Altindağ
      • Ankara, Altindağ, Turkije (Türkiye), 06250
        • Ankara University

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Being a member of the Ankara Branch of the Altı Nokta Blind Association,
  • Being a woman with visual impairment (congenital or acquired),
  • Being female,
  • Being between 40 and 60 years of age,
  • Being able to speak Turkish,
  • Having no additional communication problems other than visual impairment,
  • Having experienced at least 12 months of amenorrhea (STRAW+1 criteria).

Exclusion Criteria:

  • Refusal to participate in the study,
  • Previous participation in a structured menopause-related education program,
  • Use of pharmacological treatment for the management of menopausal symptoms,
  • Use of non-pharmacological methods for menopausal symptom management (e.g., yoga, aromatherapy, phytotherapy, etc.),
  • Surgical menopause,
  • Having additional disabilities other than visual impairment (hearing, intellectual, or physical disabilities).

Withdrawal / Discontinuation Criteria

  • Initiation of any pharmacological or non-pharmacological intervention aimed at reducing menopausal symptoms during the study period,
  • Non-adherence to the study protocol,
  • Voluntary withdrawal from the study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Audio description-based menopause education program
Participants in this arm received an audio-described menopause education program designed for women with visual impairment. The intervention aimed to improve menopause knowledge and reduce menopausal symptom-related difficulties. The educational content was delivered in an accessible format tailored to participants' needs. Outcomes were assessed using standardized measurement tools.
This intervention consisted of a structured audio-described menopause education program developed for women with visual impairment. The program provided accessible information about menopause, menopausal symptoms, and symptom management strategies to improve knowledge and awareness.
Geen tussenkomst: Standard of care
Participants in this arm did not receive the audio-described menopause education program during the study period. They continued with their usual daily life without any structured educational intervention related to menopause. Outcomes were assessed at the same time points using standardized measurement tools.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Menopause Knowledge
Tijdsspanne: Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
To assess changes in menopause knowledge following the audio-described menopause education program. The total score of the "Menopause Knowledge Scale" ranges from 14 to 70, with higher scores indicating a higher level of overall knowledge about menopause. Similarly, higher scores on the General Menopause Knowledge subscale (5-25) and the Knowledge of Menopausal Symptoms and Management subscale (9-45) indicate greater knowledge in the respective domains.
Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
Menopausal Symptom Severity
Tijdsspanne: Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
To evaluate changes in menopausal symptom severity following the audio-described menopause education program. The Menopause Rating Scale was used to assess the severity of menopausal symptoms.The total score of the scale ranges from 0 to 44. Higher total scores indicate greater severity of menopausal symptoms and a more negative impact on quality of life.
Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 februari 2025

Primaire voltooiing (Werkelijk)

15 juli 2025

Studie voltooiing (Werkelijk)

15 juli 2025

Studieregistratiedata

Eerst ingediend

3 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

17 augustus 2026

Eerst geplaatst (Werkelijk)

19 augustus 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

17 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

De-identified participant data, including baseline characteristics and outcome measures, will be shared. No identifiable personal data will be included.

IPD-tijdsbestek voor delen

De-identified individual participant data will be available beginning 6 months after publication of the study results and will remain available for 5 years.

IPD-toegangscriteria voor delen

Access to individual participant data and supporting documents will be granted to qualified researchers who submit a methodologically sound research proposal. Requests must be approved by the principal investigator or study sponsor. Data will be provided for non-commercial academic research purposes only. All data will be de-identified, and no personally identifiable information will be shared. Data will be shared via secure electronic transfer upon approval.

IPD delen Ondersteunend informatietype

  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren